新型预后模型的开发与验证:用于预测初治转移性去势敏感性前列腺癌的总生存期
本研究回顾性分析了304例在京都大学医院治疗的初治转移性去势敏感性前列腺癌患者,基于与总生存期相关的临床参数建立预后模型,并在520例独立队列中进行外部验证。模型将患者分为高、中、低危组,验证队列中位总生存期分别为41个月、63个月和未达到,Harrell C指数为0.649。
要点
- 基于疾病范围评分≥2或肝转移、乳酸脱氢酶>250U/L、原发Gleason评分5分建立预后模型。
- 高危组中位总生存期28个月,中危组59个月,低危组未达到。
- 模型简单可重复,可能有助于风险分层和治疗选择。
核心结论
- 该简单可重复的预后模型可用于初治转移性去势敏感性前列腺癌的风险分层和治疗选择。
研究设计与样本
- 回顾性综述了304例在京都大学医院治疗的患者,并在520例独立队列中进行外部验证。
主要发现
- 超过80%的队列Gleason总和评分≥8。
- CHAARTED高肿瘤负荷组(n=172)中位总生存期为53个月,低肿瘤负荷组(n=100)为131个月。
- 与总生存期独立相关的因素包括:疾病范围评分≥2或存在肝转移;乳酸脱氢酶>250U/L;原发Gleason评分5分。
- 新模型高危、中危、低危组的中位总生存期分别为28个月、59个月和未达到;验证队列相应值分别为41个月、63个月和未达到。
- Harrell C指数为0.649。
临床怎么用
- 作者认为该模型可能有助于风险分层和治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There has been growth in the treatment options for castration-sensitive metastatic prostate cancer (mPCa), but without clear guidance for risk stratification. OBJECTIVE: To identify clinical parameters associated with overall survival (OS) and establish a prognostic model for use with treatment-naïve castration-sensitive mPCa. DESIGN, SETTING, AND PARTICIPANTS: A retrospective review of 304 patients treated at Kyoto University Hospital was performed. A prognostic model was created using clinical parameters associated with OS. The model was externally validated in an independent cohort of 520 patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable analysis was performed to identify the clinical parameters associated with OS. Risk scores were calculated using Cox proportional hazards analysis for each combination of risk factors, and patients were grouped into categories based on those scores. RESULTS AND LIMITATIONS: Over 80% of the cohort had a Gleason sum score ≥8. The median OS was 53mo among patients with CHAARTED high-volume PCa (n=172) and 131mo among those with low-volume PCa (n=100). Independent factors associated with OS were extent of disease score ≥2 or the presence of liver metastasis; lactate dehydrogenase >250U/L; and a primary Gleason score of 5. The median OS for the high-, intermediate-, and low-risk groups according to the new model were 28mo, 59mo, and not reached, respectively; the corresponding values in the validation cohort were 41mo, 63mo, and not reached. Harrell's C-index was 0.649. CONCLUSIONS: Our simple and reproducible prognostic model for treatment-naïve castration-sensitive mPCa could aid in risk stratification and treatment selection. PATIENT SUMMARY: We identified clinical parameters associated with prognosis in castration-sensitive metastatic prostate cancer and established a reproducible prognostic model that could be used to guide treatment decisions.
引用
- Akamatsu S, Kubota M, Uozumi R, et al. Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer. Eur Urol Oncol. 2018. PMID: 31200847. doi:10.1016/j.euo.2018.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。